PR Newswire Clinical TrialsOriginal article
Cadence Neuroscience Receives FDA IDE Approval to Begin Multicenter Study of its Biomarker Targeted Stimulation Therapy for Focal Drug-Resistant Epilepsy
RegulatoryapprovedBiomarker Targeted Stimulation TherapyPositive
AI Analysis
Summary
Cadence Neuroscience received FDA IDE approval to initiate a multicenter BTSEE study evaluating its biomarker-targeted stimulation therapy in 45 pediatric and adult patients with focal drug-resistant epilepsy across up to 10 U.S. comprehensive epilepsy centers.
Clinical Trial Data
Patients
45
Outcome Details
FDA IDE (Investigational Device Exemption) approval granted to begin multicenter study
Importance:7/10
Sentiment:
0.80
FDA approvalIDE approvalepilepsybiomarker-guidedneurostimulationpediatricadult
Read the original article
Published by PR Newswire Clinical Trials on October 14, 2026 1:00 PM